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Abstract
Background: Substance P (SP) is produced at high levels in the central nervous system (CNS), and its target receptor,
neurokinin 1 receptor (NK-1R), is expressed by glia and leukocytes. This tachykinin functions to exacerbate inflammatory
responses at peripheral sites. Moreover, SP/NK-1R interactions have recently been associated with severe
neuroinflammation and neuronal damage. We have previously demonstrated that NK-1R antagonists can limit
neuroinflammatory damage in a mouse model of bacterial meningitis. Furthermore, we have since shown that
these agents can attenuate Borrelia burgdorferi-induced neuronal and glial inflammatory mediator production in
non-human primate brain explants and isolated neuronal cells.
Methods: In the present study, we have assessed the role played by endogenous SP/NK-1R interactions in damaging
CNS inflammation in an established rhesus macaque model that faithfully reproduces the key clinical features of Lyme
neuroborreliosis, using the specific NK-1R antagonist, aprepitant. We have utilized multiplex ELISA to quantify immune
mediator levels in cerebrospinal fluid, and RT-PCR and immunoblot analyses to quantify cytokine and NK-1R expression,
respectively, in brain cortex, dorsal root ganglia, and spinal cord tissues. In addition, we have assessed astrocyte
number/activation status in brain cortical tissue by immunofluorescence staining and confocal microscopy.
Results: We demonstrate that aprepitant treatment attenuates B. burgdorferi-induced elevations in CCL2, CXCL13,
IL-17A, and IL-6 gene expression in dorsal root ganglia, spinal cord, and/or cerebrospinal fluid of rhesus macaques at 2
to 4 weeks following intrathecal infection. In addition, we demonstrate that this selective NK-1R antagonist also prevents
increases in total cortical brain NK-1R expression and decreases in the expression of the astrocyte marker, glial fibrillary
acidic protein, associated with B. burgdorferi infection.
Conclusions: The ability of a centrally acting NK-1R inhibitor to attenuate B. burgdorferi-associated neuroinflammatory
responses and sequelae raises the intriguing possibility that such FDA-approved agents could be repurposed for use as
an adjunctive therapy for the treatment of bacterial CNS infections.
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Background
The neuropeptide substance P (SP) is produced at high
levels within the central nervous system (CNS) and its
selective receptor, the neurokinin-1 receptor (NK-1R), is
expressed by resident cells such as neurons, microglia,
and astrocytes, and by immune cells that can infiltrate the
CNS including macrophages and lymphocytes (as reviewed
in [1, 2]). In addition to its functions as a neurotransmitter
in the perception of pain and its essential role in gut
motility, this tachykinin is now recognized to exacer-
bate inflammation at peripheral sites including the skin,
lung, and gastrointestinal and urogenital tracts. Indeed,
this neuropeptide appears to contribute to disease path-
ology for some infectious agents. For example, SP in-
creases the bronchoconstriction and damaging cardiac
inflammation following infection with respiratory syn-
cytial virus and encephalomyocarditis virus, respectively
[3, 4]. Likewise, SP contributes to the severity of inflam-
mation associated with Trypanosoma brucei brucei
infection, and inflammation and granuloma size in a
mouse model of Taenia solium cysticercosis [5–7].
Recently, a number of studies have identified a similar
role for SP and NK-1R interactions in neuroinflamma-
tion (as discussed in [1, 2]), and our data suggest that
SP exacerbates damaging inflammation elicited within
the CNS in response to disparate bacterial pathogens.
We determined that the absence of SP/NK-1R interac-
tions in SP receptor-deficient mice or prophylactic
pharmacological NK-1R inhibition in wild type animals
significantly reduces bacteria-induced neuroinflamma-
tion and resultant CNS damage [8, 9]. NK-1R null mice
and mice treated with an NK-1R antagonist showed
reduced inflammatory and maintained immunosuppres-
sive, cytokine production, as well as decreased astroglio-
sis, cellularity, and demyelination following intracerebral
administration of the Gram-negative bacterial patho-
gens Neisseria meningiditis and Borrelia burgdorferi,
or the Gram-positive bacterium Streptococcus pneumo-
niae [8, 9]. These rodent studies therefore indicate that
SP/NK-1R interactions are essential for the progression
of damaging inflammation following bacterial CNS
infection.
In the present study, we have assessed the role played
by endogenous SP/NK-1R interactions in damaging CNS
inflammation in an established nonhuman primate (NHP)
model of Lyme neuroborreliosis using the specific NK-1R
antagonist, aprepitant [10]. We have previously demon-
strated that this NHP model faithfully reproduces the key
features of neuroborreliosis including the development of
pleocytosis, as well as the classical lesions associated with
leptomeningitis of the brain and spinal cord and radiculitis
observed in human patients with B. burgdorferi-associated
CNS infection [11]. We demonstrate that inhibition of
SP/NK-1R interactions limits inflammatory nervous
system immune responses associated with intrathecal
B. burgdorferi administration in rhesus macaques. This
ability, and the availability of centrally acting NK-1R
inhibitors that are approved for clinical use, raises the in-
triguing possibility that targeting SP/NK-1R interactions
could be useful as an adjunctive therapy for the treatment
of bacterial CNS infections.
Methods
Spirochetal inoculum
First passage B. burgdorferi strain B31 clone 5A19 spiro-
chetes, isolated from an ear biopsy of a previously in-
fected mouse, were grown in Barbour-Stoenner-Kelly-H
medium supplemented with 6% rabbit serum and antibio-
tics (rifampicin at 45.4 μg/mL, phosphomycin at 193 μg/
ml, and amphotericin at 0.25 μg/ml; Sigma-Aldrich, St.
Louis, MO) to late logarithmic phase under microaero-
philic conditions. An inoculum containing 1 × 108 spiro-
chetes/ml in RPMI 1640 medium (Invitrogen, USA) was
prepared as previously described [11].
Animals
Twenty 2.5 to 5.5-year-old rhesus macaques (Macaca
mulatta) of Chinese origin were used in this study. All
protocols were approved by the Institutional Animal
Care and Use Committee of the Tulane National Pri-
mate Research Center. Fifteen rhesus macaques were
anesthetized and inoculated intrathecally with 1 × 108 live
spirochetes into the cisterna magna, whereas five rhesus
macaques were left uninfected and received 1 ml of RPMI
1640 medium after removing an equivalent volume of
CSF. The establishment of in vivo B. burgdorferi infection
was confirmed by positive culture from at least necropsy
tissue sample. The first set of animals were studied for
2 weeks and included two control animals (one of which
was treated with aprepitant), two infected and untreated
animals, and two infected animals that were treated with
aprepitant. The second set of animals were studied for
4 weeks and included three control animals (one of which
was treated with aprepitant), five infected and untreated
animals, and four infected animals treated with aprepitant.
Animals received an average dose of aprepitant (Merck &
Co, Inc., Whitehouse Station, NJ) of 28 ± 6 mg/kg per
day p.o. daily, and drug treatments were started 2 days
before inoculation. These doses are consistent with
standard veterinary regimens for the chosen drugs in
NHP, and the 4-week duration of the study precluded
the development of neural pathology that we have dem-
onstrated occurs at 8 weeks following B. burgdorferi in-
fection [12].
RNA extraction and reverse transcription
Total RNA was extracted using Trizol (Thermo Fisher
Scientific, Waltham, MA), and in some experiments was
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further purified with the RNeasy kit (Qiagen, Hilden,
Germany) as previously described [13]. RNA quantity
and quality were assessed using a Nanodrop ND-1000
spectrophotometer prior to generating cDNA using
the high capacity RNA-to-cDNA™ Kit (Thermo Fisher
Scientific) according to the manufacturer’s instructions,
or the Promega M-MLV protocol (Promega, USA).
Semi-quantitative reverse transcription-PCR and quantitative
real-time PCR
Promega flexi was utilized in semi quantitative reverse
transcription-PCR (RT-PCR) to assess levels of mRNA
encoding NK-1R as previously described [13, 14], and
quantification was performed using Bio-Rad ImageLab
software and normalized to the expression of GAPDH
determined in parallel RT-PCR reactions. In addition,
the levels of 24 genes known to be involved in the in-
flammatory response and neurogenic inflammation, and
two housekeeping genes, were determined by reverse
transcription quantitative real-time PCR (RT-qPCR). All
primers were designed to span an exon-exon junction
using primer-BLAST (NCBI) and SYBR® Green qPCR
assays were performed using a 7900 Real-Time PCR
System (Applied Biosystems, USA) as previously de-
scribed [14]. Primer specificity was assessed from the
melting curves generated after 40 cycles.
Immunoblot analysis
Homogenates from NHP frontal cortical tissue were
analyzed by immunoblot analysis as we have previously
described [14, 15] using a mouse monoclonal antibody
directed against human NK-1R (ThermoFisher Scientific;
clone ZN003). Protein bands were detected using a Bio-
Rad ChemiDoc imaging system and quantification ana-
lysis was performed using ImageLab software (Bio-Rad)
normalized to the expression of the housekeeping gene
product β-actin.
BioPlex cytokine protein expression analysis
Cerebrospinal fluid (CSF) samples were collected from
each animal at baseline and weeks 1, 2, 3, and 4, follow-
ing infection and the concentration of cytokines and
chemokines present in the (CSF) was quantified using
the Bio-Plex Pro™ Human Cytokine 27-plex Assay kit
(Bio-Rad, Hercules, CA) following the manufacturer’s
instructions. The multiplex plate was read using a Bio-
Plex 200 Suspension Array Luminex System (Bio-Rad).
Fluorescent immunohistochemical analysis
NHP frontal cortical tissue samples were fixed with 4%
paraformaldehyde, mounted in optimal cutting temperature
medium and flash frozen, sectioned (16 μm) at 21 °C, and
subsequently stored at −80 °C. Randomly selected sections
were permeabilized with either 0.1% Triton X100 and 0.2%
cold-water fish gelatin in 1× phosphate buffered saline, or
1:1 methanol to acetone, for 1 h prior to immunofluores-
cent staining. Samples were blocked with 5% normal goat
serum at room temperature and a primary fluorochrome
conjugated antibody directed against glial fibrillary acidic
protein (GFAP) (Abcam; clone EPR1034Y) or an unconju-
gated antibody against NK-1R (ThermoFisher Scientific;
clone ZN003) was added overnight at 4 °C. A fluorochrome
conjugated secondary antibody to detect anti-NK-1R
staining was incubated at room temperature for 1 h
and coverslips were mounted with Prolong Gold with
DAPI. Samples were analyzed using an Olympus IX70
Fluoview 1000 confocal microscope, and multiple images
were captured in five random fields for each section. Cell-
Profiler was utilized to quantify the mean fluorescent inten-
sity for confocal images. Data is shown as mean fluorescent
intensity normalized to the number of cells [16].
Statistical analysis
Data is presented as the mean ± standard deviation (SD).
Statistical analyses were performed using one-way analysis
of variance (ANOVA) with Bonferroni’s or Tukey’s post
hoc tests as appropriate using commercially available soft-
ware (GraphPad Prism, GraphPad Software, La Jolla, CA).
In all experiments, results were considered statistically sig-
nificant when a P value of less than 0.05 was obtained.
Results
Cortical brain NK-1R expression increases in a SP/NK-1R
interaction-dependent manner in a non-human primate
model of Lyme neuroborreliosis
To begin to determine the role of SP/NK-1R interactions
in neuroinflammation associated with B. burgdorferi
infection of the CNS in NHPs, we assessed NK-1R ex-
pression levels in the brain cortex of rhesus macaques at
rest and following intrathecal B. burgdorferi infection
(1 × 108 bacteria). As shown in Fig. 1, expression of
mRNA encoding NK-1R was significantly increased in
the brain cortex at 2 weeks following infection and an
elevation in NK-1R protein expression was observed al-
though this effect failed to reach statistical significance.
The effect of B. burgdorferi on NK-1R mRNA expression
was reversed by 4 weeks following infection (Fig. 1a, b).
Interestingly, the increases in NK-1R mRNA expression
and the tendency to increase NK-1R protein levels at 2
weeks following infection, were not seen in animals that
received treatment with the NK-1R-specific antagonist
aprepitant (125 mg daily p.o) (Fig. 1).
B. burgdorferi-induced increases in CSF levels of CCL2 in
infected NHPs are attenuated by treatment with an NK-1R
antagonist
Multiplex cytokine assay analysis showed that levels of
the inflammatory chemokines CCL2 and CXCL8, and
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the cytokine IL-6 were significantly elevated in the CSF
of infected rhesus macaques at 2 weeks following intra-
thecal B. burgdorferi infection (Fig. 2a and data not
shown). Importantly, treatment with aprepitant signifi-
cantly attenuated increases in CCL2 protein levels at
2 weeks following infection in this experimental series
(Fig. 2a).
However, this result was not longitudinally reprodu-
cible in CSF samples from a second experimental series
followed over 4 weeks post-infection as these animals
showed a lower average inflammatory response to infec-
tion (Fig. 2b and data not shown). We surmised that this
might be due to the confounding influence of multiple
CNS regions on CSF cytokine concentrations obscuring
aprepitant treatment effects. Therefore, we subsequently
evaluated cytokine transcription in specific regions of
the CNS that demonstrated a high number of inflamma-
tory lesions per unit area as assessed by a pathologist.
These regions included the dura mater and spinal cord,
and dorsal root ganglia (DRG).
B. burgdorferi-induced increases in CXCL13 and CCL2
mRNA expression in the DRG of infected NHPs are
attenuated by NK-1R antagonist treatment
Analysis of mRNA expression in pooled DRG revealed
that expression of mRNA encoding CXCL13 was signifi-
cantly elevated at 2 and 4 weeks following B. burgdorferi
administration (Fig. 3a, b), while levels of CCL2 mRNA
were higher at 4 weeks following infection (Fig. 3c).
Importantly, daily treatment with aprepitant significantly
attenuated infection-associated increases in CXCL13 and
CCL2 mRNA expression (Fig. 3).
B. burgdorferi-induced increases in inflammatory cytokine
and chemokine mRNA expression in the dura mater and
spinal cord of infected NHPs are attenuated by NK-1R
antagonist treatment
Analysis of mRNA expression in the dura mater and
spinal cord within the cervical region revealed that ex-
pression of mRNA encoding CXCL13, CCL2, and IL-
17A was significantly elevated at 2 weeks following B.
burgdorferi administration (Fig. 4a–c), while levels of
mRNA encoding IL-6 were higher at 4 weeks following
infection (Fig. 4d). Similarly, levels of mRNA encoding
IL-17A were higher in thoracic region dura mater and
spinal cord at 2 weeks following B. burgdorferi challenge
(Fig. 4e). Importantly, daily treatment with aprepitant
significantly attenuated these infection-associated in-
creases in inflammatory mediator mRNA expression
(Fig. 4).
B. burgdorferi-induced decreases in cortical astrocyte
marker expression are attenuated by NK-1R antagonist
treatment
To further assess the role of SP/NK-1R interactions in
neuroinflammation in NHPs, we assessed the relative ex-
pression of the astrocyte marker GFAP in the brain cor-
tex of uninfected animals and following B. burgdorferi
infection. Immunofluorescent staining of NHP frontal
cortex tissue demonstrated that levels of GFAP ex-
pression are decreased at 2 and 4 weeks following B.
burgdorferi administration (Fig. 5). Interestingly, infection-
associated decreases in GFAP expression were significantly
attenuated in animals that received the NK-1R antagonist
aprepitant.
Fig. 1 In vivo NHP infection with B. burgdorferi increases NK-1R expression in the CNS, and such increases are prevented by treatment with the
NK-1R antagonist aprepitant. Rhesus macaques were uninfected (n = 2 animals) or infected intrathecally with B. burgdorferi (Bb, 1 × 108 bacteria;
n = 8), and infected animals were either untreated (n = 4) or treated with aprepitant (n = 4) for 2 or 4 weeks prior to euthanasia. Expression of
mRNA encoding NK-1R in frontal cortical tissue samples was determined by RT-PCR (a) and relative expression normalized to GAPDH levels was
determined by densitometric analysis (b). NK-1R protein expression was determined in tissue samples by immunoblot analysis and normalized to
β-actin expression (c). Data is expressed as the mean ± SD. Asterisk and pound symbols indicate statistically significant difference from uninfected
animals and untreated infected animals, respectively (p < 0.05)
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Discussion
Bacterial infections of the CNS constitute a group of
highly damaging and often life-threatening diseases.
What makes the etiology of these diseases so perplexing
is that severe CNS inflammation can be initiated by bac-
terial species that are generally regarded to be of low
virulence [17]. While such responses may be protective,
inflammation elicited by infectious agents often results
in progressive CNS damage. Indeed, we have recently
demonstrated that inflammation plays a key role in
pathogenesis in a NHP model of acute Lyme neurobor-
reliosis [12]. A hallmark of developing inflammation is
the synergistic interaction between cells and their products
that can amplify the response. It is now widely accepted
that SP, the most abundant tachykinin in the CNS, can
exacerbate the inflammatory responses of both leuko-
cytes and resident glial cells via the high affinity NK-1R
(as reviewed in [1, 2]). Importantly, we have demon-
strated that SP can augment proinflammatory mediator
production by murine glia in response to B. burgdorferi [9].
Consistent with this finding, we have shown that endogen-
ous SP/NK-1R interactions are required for maximal pro-
inflammatory cytokine expression in vivo following direct
CNS administration of this spirochete in mice [9]. More
recently, we have shown that an NK-1R antagonist can at-
tenuate the neuronal and glial production of inflammatory
mediators including CCL2 and IL-6 in rhesus macaque
Fig. 2 Aprepitant treatment prevents B. burgdorferi-induced increases
in CCL2 protein levels in the CSF of NHPs. Rhesus macaques were
uninfected (n = 5 animals) or infected intrathecally with B. burgdorferi
(Bb, 1 × 108 bacteria; n = 15) and were untreated (n = 7) or treated with
aprepitant (Ap, n = 8) for 2 (a) or 4 (b) weeks. Expression of CCL2 in
CSF was determined by multiplex analysis. Data is expressed as the
mean ± SD and asterisks indicate statistically significant differences
between the untreated and treated groups (p < 0.05)
Fig. 3 Aprepitant treatment prevents B. burgdorferi-induced increases
in CCL2 and CXCL13 mRNA expression in the dorsal root ganglia of
NHPs. Rhesus macaques were uninfected (n = 5 animals) or infected
intrathecally with B. burgdorferi (Bb, 1 × 108 bacteria; n = 15), and were
untreated (n = 7) or treated with aprepitant (Ap, n = 8) for 2 (a) or 4 (b, c)
weeks. The level of expression of mRNA encoding CXCL13 (a, b) and
CCL2 (c) in the dorsal root ganglia was determined by qPCR. Data is
expressed as the mean ± SD and asterisks indicate statistically significant
differences between the untreated and treated groups (p< 0.05)
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frontal cortex explants and isolated DRG cells following
B. burgdorferi challenge [18].
In the present study, we have confirmed that levels of
gene expression of select inflammatory cytokines and
chemokines, including CCL2, CXCL13, IL-17A, and IL-
6, are increased in the DRG and spinal cord tissue sam-
ples and the CSF from rhesus macaques at 2 to 4 weeks
following intrathecal B. burgdorferi administration. An
increase in IL-17A gene expression following infection is
particularly interesting since cell signaling mediated by
this cytokine plays a key role in regulating the expres-
sion of other inflammatory mediators, such as IL-6, via a
mechanism that involves NF-κB-mediated transcription
[19]. Consistent with our previous studies using frontal
cortex explants and isolated DRG cells [12], treatment
with the NK-1R antagonist, aprepitant, was able to signifi-
cantly attenuate the transcription of inflammatory media-
tors in our in vivo NHP model of Lyme neuroborreliosis.
Taken together, these data support the contention that en-
dogenous SP/NK-1R interactions play a significant role in
the initiation and/or progression of neuroinflammation
associated with B. burgdorferi infection of the CNS.
Interestingly, our studies also demonstrate that NK-1R
expression is increased in the NHP brain cortex at 2
weeks following infection and that this effect can be
abolished by treatment with aprepitant. While the
mechanisms underlying the ability of B. burgdorferi to
increase NK-1R expression are not clear, this finding is
in agreement with previous studies demonstrating the
ability of bacteria and/or their products to upregulate
NK-1R expression by leukocytes [20, 21]. However, the
ability of aprepitant to prevent increases in NK-1R expres-
sion suggests that B. burgdorferi-induced effects occur
secondary to a response that is, at least in part, dependent
upon SP/NK-1R interactions. This would be consistent
with the documented ability of inflammatory mediators
to increase NK-1R expression by leukocytes [20, 21]
and glial cells [22].
Finally, our immunohistochemistry analysis of NHP
frontal cortex tissue demonstrates that the number and/or
activation level of astrocytes as determined by GFAP ex-
pression is decreased in NHPs at 2 and 4 weeks following
B. burgdorferi administration. While the mechanisms
Fig. 4 Aprepitant treatment prevents B. burgdorferi-induced increases in
CCL2, CXCL13, IL-17A, and IL-6 mRNA expression in the spinal cord of
NHPs. Rhesus macaques were uninfected (n = 5 animals) or infected
intrathecally with B. burgdorferi (Bb, 1 × 108 bacteria; n = 15) and were
untreated (n = 7) or treated with aprepitant (Ap, n = 8) for 2 (a–c, e) or 4
(d) weeks. The level of expression of mRNA encoding CCL2 (a), CXCL13
(b), IL-17A (c, e), and IL-6 (d) in the spinal cord cervical (a–d) and
thoracic (e) regions was determined by qPCR. Data is expressed as the
mean ± SD and asterisks indicate statistically significant differences
between the untreated and treated infected animal groups (p < 0.05)
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underlying this effect are unclear, decreases in astrocyte
number/activation may result from increased apoptotic
death of this population following infection or could occur
as a result of the compensatory production of suppressive
mediators, such as IL-10 and IL-19, that have been shown
to be produced in a delayed manner by B. burgdorferi-
challenged microglia and/or astrocytes [14, 23]. Interest-
ingly, treatment with aprepitant prevented B. burgdorferi-
induced decreases in GFAP expression indicating that this
effect, either directly or indirectly, is mediated by en-
dogenous SP/NK-1R interactions.
Non-peptide NK-1 receptor antagonists are known to
exert central effects [24]. Of the latest generation of NK-
1R antagonists, aprepitant has been shown to cross the
blood-brain barrier after oral administration using hu-
man positron emission tomography to demonstrate its
ability to occupy NK-1R within the brain in an oral dose
and plasma concentration-dependent manner [25]. The
ability of NK-1R antagonists to cross the blood-brain
barrier means that these agents have the potential for
use in the treatment of a wide range of CNS disorders
[26–29]. Inhibitors of this tachykinin receptor have been
the subject of extensive study for the clinical treatment
of depression and anxiety, and aprepitant and its pro-
drug fosaprepitant are currently employed clinically as
post-chemotherapy anti-emetic agents [10]. While we
did not formally investigate the safety of aprepitant in
this study, no adverse events were recorded for any of
the animals receiving this drug that could be attributed
to the treatment at any point in the study period. This
agrees with other studies in which aprepitant was used
(performed both in humans and in mice), where no
safety issues were detected [30, 31].
Given a potential role for SP/NK-1R interactions in
damaging inflammatory responses within the CNS fol-
lowing infection, there has been considerable interest in
targeting this receptor to limit neuroinflammation and
neurological sequelae associated with infectious agents.
For example, an NK-1R antagonist has been shown to
prevent seizure activity in a rodent model of helminth
brain infection [32], while our own studies have shown
that pharmacological targeting of NK-1R with the antag-
onist L703,606 can not only prevent the development of
damaging inflammation due to streptococcal CNS infec-
tion when administered prophylactically but can also re-
verse infection-associated gliosis and demyelination
when delivered therapeutically without increasing CNS
bacterial burden [8]. Furthermore, aprepitant has been
tested as an adjunctive therapy for the treatment of
HIV-associated neurocognitive disorder in human clin-
ical trials and has been shown to reduce in vivo serum
levels of several pro-inflammatory cytokines and chemo-
kines, and lower CD4-positive T cell expression of
sCD163 and PD-1 [33, 34]. As such, while further studies
are needed to define the specific mechanisms underlying
the ability of SP to augment CNS inflammation and its
role in pathogen clearance, the available data raise the in-
triguing possibility that currently approved NK-1R antago-
nists, such as aprepitant, could be repurposed for use as a
co-therapy to limit the neuroinflammatory damage associ-
ated with infectious agents. Clearly, further investigation
of the prophylactic and therapeutic benefits of NK-1R an-
tagonists in such conditions is warranted.
Conclusions
Our results indicate that NK-1R antagonist treatment can
attenuate aspects of bacterially induced inflammatory re-
sponses in CNS tissues in an in vivo NHP model of Lyme
neuroborreliosis. Thus, in addition to antibiotics, treat-
ment with clinically approved NK-1R antagonists could be
explored as an adjuvant intervention against neuroinflam-
matory damage associated with infectious agents.
Fig. 5 Aprepitant treatment attenuates B. burgdorferi infection-induced reductions in astrocyte activity/numbers. Rhesus macaques were uninfected orx
infected intrathecally with B. burgdorferi (Bb, 1 × 108 bacteria) and were untreated or treated with aprepitant (Ap) for 2 or 4 weeks prior to euthanasia.
GFAP expression in frontal cortical tissue samples at 2 (a) and 4 (b) weeks following infection was determined by immunofluorescence microscopy.
Relative GFAP expression in two fields of three sections from an animal in each group is shown and data is expressed as the mean ± SD. Asterisk and
pound symbols indicate statistically significant difference from uninfected animals and untreated infected animals, respectively (p < 0.05)
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